Purchase one-time access:Academic and Personal
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the Merlin-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in non–ST-elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial.J Am Coll Cardiol. 2009; 53: 1411-1421
- Relationship between nonsustained ventricular tachycardia after non–ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in non–ST-segment elevation acute coronary syndrome–Thrombolysis In Myocardial Infarction 36 (Merlin-TIMI 36) randomized controlled trial.Circulation. 2010; 122: 455-462
- Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients.Eur Heart J. 2001; 22: 1997-2006
- Nonsustained ventricular tachycardia in the setting of acute myocardial infarction: tachycardia characteristics and their prognostic implications.Circulation. 1998; 98: 2030-2036
- Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era: GISSI-2 results.Circulation. 1993; 87: 312-322
- Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction.Am J Cardiol. 1986; 58: 1151-1160
- Long-term prognosis in unstable angina: the importance of early risk stratification using continuous ST segment monitoring.Eur Heart J. 1998; 19: 240-249
- Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina.N Engl J Med. 1986; 314: 1214-1219
- Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the Merlin-TIMI 36 randomized trial.JAMA. 2007; 297: 1775-1783
- Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in non–ST-segment elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.Am Heart J. 2006; 151: e1-e9
- Clinical classification of cardiac deaths.Circulation. 1982; 65: 457-464
- Blood levels of long-chain n-3 fatty acids and the risk of sudden death.N Engl J Med. 2002; 346: 1113-1118
- Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.JAMA. 2005; 294: 2866-2871
- The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.JAMA. 2000; 284: 835-842
- Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.Stat Med. 2008; 27: 157-172
- 2007 Guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/non-ST-Elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.J Am Coll Cardiol. 2007; 50: e1-e157
- Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.N Engl J Med. 2004; 351: 2481-2488
- Defibrillator implantation early after myocardial infarction.N Engl J Med. 2009; 361: 1427-1436
CV Therapeutics (now Gilead Science, Inc., Foster City, California) supported the MERLIN-TIMI 36 trial but had no involvement in funding the present analysis.
Dr. Scirica has served as a consultant for Lexicon Pharmaceutical, The Woodlands, Texas, Arena Pharmaceuticals, San Diego, California, Gilead Sciences, Foster City, California, and Shionegi, Florham Park, New Jersey; and is the recipient of an unrestricted research grant from the Michael Lerner Foundation and research funding from Gilead Sciences, Foster City, California, and Daiichi-Sankyo, Parsipanny, New Jersey. Dr. Morrow has received honoraria for educational presentations from CV Therapeutics and Sanofi-Aventis, Bridgewater, New Jersey, serving as a consultant for GlaxoSmithKline, Philadelphia, Pennsylvania, and Sanofi-Aventis, and being on an advisory board for Genentech, San Francisco, California. Dr. Budaj receives honoraria from CV Therapeutics, AstraZeneca Wilmington, Delaware, GlaxoSmithKline, Boehringer Ingelheim, Ingelheim am Rhein, Germany, and Sanofi-Aventis and serves as a consultant to GlaxoSmithKline and Sanofi-Aventis. Dr. Lopez-Sendon has received research grants from Novartis .